Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1694515

registered interest
date	07/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what her Department's policy is on maintaining (a) supply of and (b) access to commonly prescribed medicines.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	17636
answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global, and supply disruption is an issue which affects countries all around the world.</p><p>There are a number of reasons why supply can be disrupted, including manufacturing difficulties, regulatory non-compliance, access to raw materials, sudden demand spikes, or distribution issues. Supply issues are driven by a range of factors, many of which are non-specific to the United Kingdom.</p><p>Whilst we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and help mitigate risks to patients. We work closely with industry, the National Health Service, and others, to develop bespoke mitigation plans, which are tailored to each issue, to help ensure patients continue to have access to the medicines they need.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 10:06:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4603 label Biography information for Preet Kaur Gill

1680961

registered interest
date	09/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent progress her Department has made on consulting on proposed amendments to Part IX of the Drug Tariff; and if she will make an assessment of the potential impact of the proposed amendments on (a) the medical technology ecosystem, (b) innovation relating to the the Life Sciences Vision and (c) the wider UK economy.
tabling member constituency	Dewsbury
tabling member printed	Mark Eastwood
uin	8860
answer	answer is ministerial correction date of answer 16/01/2024 answer text <p>A targeted consultation on Medical Devices in Primary Care: Proposals for updating Part IX of the Drug Tariff-medical devices available for prescribing in primary care was issued on 6 October 2023.</p><p> </p><p>The consultation on Part IX of the Drug Tariff sets out a series of proposals to modernise Part IX of the Drug Tariff. The objectives of the proposals are to ensure Part IX consistently includes devices that are of good quality and effectiveness; ensure that the Tariff product list is refreshed going forward and existing and new products are only adopted or continued to be used if able to demonstrate value to the National Health Service and patients; and update processes on Part IX applications to support the adoption of innovation that can improve patient outcomes and the quality of life for patients.</p><p> </p><p>The consultation was fully closed for responses at 4 January 2024. The Department is considering all the responses before finalising any proposed amendments to Part IX of the Drug Tariff. Therefore, the Department will share a response to the consultation and an updated assessment of the impacts in due course.</p><p> </p><p>In forming the proposals, that have been consulted on, the department has had extensive engagement with industry, the health and care sector, NHS commissioners and patient representative groups. There will be further engagement with these stakeholders for any amendments to Part IX that are taken forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 9098 question first answered 16/01/2024 10:32:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4807 label Biography information for Mark Eastwood

1668572

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure adequate levels of supply of medication prescribed for (a) epilepsy, (b) hormone replacement therapy and (c) ADHD.
tabling member constituency	Bedford
tabling member printed	Mohammad Yasin
uin	882
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The Department has well-established procedures to deal with medicine shortages and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.</p><p>We are aware of a current supply issue with generic lamotrigine 5mg dispersible tablets for epilepsy. We have issued comprehensive management guidance to the National Health Service highlighting the availability of alternative products.</p><p>There have been issues with the supply of a limited number of hormone replacement therapy (HRT) products, primarily due to very sharp increases in demand, but the supply position for many of those products has improved considerably over the last year. Only one of the 23 Serious Shortage Protocols issued since April 2022 remains in place. We continue to engage with suppliers individually to address these issues and improve resilience in the short, medium and long term. We are also holding quarterly roundtables with manufacturers, wholesalers and community pharmacists to monitor progress and agree what more needs to be done to ensure supply is sufficient to meet demand. The eighth HRT supply roundtable is expected to be held in January 2024.</p><p>We are aware of disruptions to the global supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues are now resolving. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. We are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/11/2023 10:45:48 answering member 4423 label Biography information for Will Quince
tabling member	4598 label Biography information for Mohammad Yasin

1666928

registered interest
date	24/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what recent analysis they have undertaken of the approval thresholds used by the National Institute for Health and Care Excellence (NICE) to approve new medications.
tabling member printed	Baroness Merron
uin	HL10783
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.</p> answering member printed Lord Markham question first answered 26/10/2023 09:42:54 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron

1664972

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the level of availability of prescription drugs from unregulated sources.
tabling member constituency	Witham
tabling member printed	Priti Patel
uin	202666
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulator within the United Kingdom for human medicines and is responsible for enforcing the Human Medicines Regulations 2012. The MHRA has identified the illegal sale and supply of human medicines as a global challenge. This includes the sale of prescription drugs from unregulated sources. Criminal gangs, often based overseas, advertise medicines through websites resembling those of legitimate pharmacies, while others exploit online marketplaces or sell social media platforms.</p><p>The MHRA has a dedicated Criminal Enforcement Unit (CEU) that works with partners across government and policing to prevent and disrupt this illegal trade and to bring to justice those involved. The CEU monitors online channels for evidence of illegal activity and takes proportionate regulatory action. This includes using the full range of the agency’s powers to investigate and prosecute offenders where necessary and appropriate. The unit also works to remove illegally trading websites and remove criminal profits from offenders. Through its #Fakemeds communications campaign the MHRA also provides quick and easy tools to help the public avoid buying illegally traded medicines when they shop online.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 202667 question first answered 20/10/2023 11:21:17 answering member 4423 label Biography information for Will Quince
tabling member	4066 label Biography information for Priti Patel

1658670

registered interest
date	06/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when his Department plans to publish a (a) response to the consultation on hub and spoke dispensing and (b) timetable for the implementation of secondary legislation.
tabling member constituency	Wakefield
tabling member printed	Simon Lightwood
uin	198248
answer	answer is ministerial correction date of answer 11/09/2023 answer text <p>We are finalising our response to the consultation and the timetable for bringing forward the implementing of the legislation and our aim is to publish this as soon as possible. The timetable for bringing forward the implementing legislation will be dependent on the availability of Parliamentary time across the four nations.</p><p>We are committed to pursuing legislative changes to level the playing field and enable all community pharmacies to make use of hub and spoke arrangements.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 11/09/2023 15:25:38 answering member 4679 label Biography information for Neil O'Brien
tabling member	4943 label Biography information for Simon Lightwood

1656692

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 27 January 2021 to Question 137239 on Prescription Drugs, what information his Department holds on the number of unique patients who have been prescribed drugs categorised under the drug groups (a) benzodiazepines including clonazepam, (b) z-drugs, (c) antidepressants and (d) opioids in the each of the last two years.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	196444
answer	answer is ministerial correction date of answer 15/09/2023 answer text <p>The methodologies used by the NHS Business Services Authority (NHSBSA) for calculating these statistics have changed since January 2021. Therefore, the below tables include data for each of the last five financial years to address the additional two-year datasets requested as well as reflect the new methodologies used.</p><p>The following table shows the number of unique patients who were prescribed benzodiazepines including clonazepam in each financial year 2018/2019 to 2022/2023:</p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Total number of unique identified patients - benzodiazepines including clonazepam</p></td><td><p>Percentage (%) of items where the patient has been identified</p></td></tr><tr><td><p>2018/2019</p></td><td><p>1,545,014</p></td><td><p>95.27</p></td></tr><tr><td><p>2019/2020</p></td><td><p>1,497,077</p></td><td><p>95.97</p></td></tr><tr><td><p>2020/2021</p></td><td><p>1,368,092</p></td><td><p>97.16</p></td></tr><tr><td><p>2021/2022</p></td><td><p>1,339,417</p></td><td><p>97.23</p></td></tr><tr><td><p>2022/2023</p></td><td><p>1,324,792</p></td><td><p>97.21</p></td></tr></tbody></table><p> </p><p>The following table shows the number of unique patients who were prescribed Z-Drugs in each financial year from 2018/2019 to 2021/2022:</p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Total number of unique identified patients – Z-Drugs</p></td><td><p>Percentage (%) of items where the patient has been identified</p></td></tr><tr><td><p>2018/2019</p></td><td><p>945,510</p></td><td><p>96.65</p></td></tr><tr><td><p>2019/2020</p></td><td><p>897,451</p></td><td><p>96.94</p></td></tr><tr><td><p>2020/2021</p></td><td><p>876,746</p></td><td><p>98.05</p></td></tr><tr><td><p>2021/2022</p></td><td><p>825,382</p></td><td><p>98.12</p></td></tr></tbody></table><p> </p><p>The following table shows the number of unique patients who were prescribed an antidepressant in each financial year from 2018/2019 to 2022/2023:</p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Total number of unique identified patients – Antidepressants</p></td><td><p>Percentage (%) of items where the patient has been identified</p></td></tr><tr><td><p>2018/2019</p></td><td><p>7,590,802</p></td><td><p>97.92</p></td></tr><tr><td><p>2019/2020</p></td><td><p>7,856,297</p></td><td><p>98.21</p></td></tr><tr><td><p>2020/2021</p></td><td><p>7,909,516</p></td><td><p>99.10</p></td></tr><tr><td><p>2021/2022</p></td><td><p>8,359,838</p></td><td><p>99.14</p></td></tr><tr><td><p>2022/2023</p></td><td><p>8,563,148</p></td><td><p>99.16</p></td></tr></tbody></table><p> </p><p> </p><p>The following table shows the number of unique patients who were prescribed opioids from financial year 2018/2019 to 2021/2022:</p><p> </p><table><tbody><tr><td><p>Financial Year</p></td><td><p>Total number of unique identified patients - Opioids (includes compound analgesics)</p></td><td><p>Percentage (%) of items where the patient has been identified</p></td><td><p>Total number of unique identified patients - Opioid Analgesics (excludes compound analgesics)</p></td></tr><tr><td><p>2018/2019</p></td><td><p>5,935,454</p></td><td><p>96.65</p></td><td><p>3,036,777</p></td></tr><tr><td><p>2019/2020</p></td><td><p>5,730,095</p></td><td><p>96.94</p></td><td><p>2,971,092</p></td></tr><tr><td><p>2020/2021</p></td><td><p>5,525,899</p></td><td><p>98.05</p></td><td><p>2,883,897</p></td></tr><tr><td><p>2021/2022</p></td><td><p>5,589,348</p></td><td><p>98.12</p></td><td><p>2,927,983</p></td></tr></tbody></table><p> </p><p>Note: Our reply to the previous question predated the official statistics used here, and used a different classification of opioids using the standard classification used in the NHSBSA Data Warehouse. Comparable data is shown in the final column of the above table; this counts patients without including any prescriptions for compound analgesics such as co-codamol and co-dydramol.</p><p><strong> </strong></p><p>All figures included above are correct as of 5 September 2023 and could be subject to revision once audited reports are published.</p> answering member constituency Colchester answering member printed Will Quince question first answered 15/09/2023 11:41:53 answering member 4423 label Biography information for Will Quince
tabling member	4436 label Biography information for Cat Smith

1641485

registered interest
date	02/06/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has held recent discussions with relevant stakeholders on taking steps to ensure an adequate supply of prescription drugs in summer 2023.
tabling member constituency	St Albans
tabling member printed	Daisy Cooper
uin	187472
answer	answer is ministerial correction date of answer 13/06/2023 answer text <p>The Department regularly holds discussions with stakeholders to ensure continuity of supply of medicines to the National Health Service. We have well-established processes to manage and mitigate medicine supply issues, working closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, Devolved Governments and others operating in the supply chain, to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/06/2023 11:51:24 answering member 4423 label Biography information for Will Quince
tabling member	4769 label Biography information for Daisy Cooper

1629047

registered interest
date	19/05/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of products approved by the National Institute for Health and Care Excellence did not appear on local formularies within 90 days of its approval in the last 12 months.
tabling member constituency	Swansea East
tabling member printed	Carolyn Harris
uin	185937
answer	answer is ministerial correction date of answer 25/05/2023 answer text <p>Information on the inclusion of products recommended by the National Institute for Health and Care Excellence (NICE) on local formularies is not held centrally.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/05/2023 13:57:39 answering member 4423 label Biography information for Will Quince
tabling member	4480 label Biography information for Carolyn Harris

1629049

registered interest
date	19/05/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an estimate of the number and proportion of medicines that were prescribed by doctors that were not available on local formularies in the last 12 months; and if he will make an assessment of the impact of medicine availability on prescriptions made by doctors.
tabling member constituency	Swansea East
tabling member printed	Carolyn Harris
uin	185938
answer	answer is ministerial correction date of answer 30/05/2023 answer text <p>No estimate has been made as the information requested is not held centrally. The purpose of a formulary is to guide prescribers to preferred products rather than mandating what they can and cannot prescribe. Prescribers are still able to prescribe medicines that are not listed on a formulary.</p> answering member constituency Colchester answering member printed Will Quince question first answered 30/05/2023 15:34:01 answering member 4423 label Biography information for Will Quince
tabling member	4480 label Biography information for Carolyn Harris